KinoPharma
Antiviral Company
Developing safe topical treatment for cervical intraepithelial neoplasia (CIN),
human papillomavirus (HPV) infection of the cervix that could potentially lead to cervical cancer.
- All
- Press Release
- Announcement
2023/06/12Announcement
Patient enrollment has begun for a Phase II clinical trial for common warts.
For details, please refer to the following website.
2023/04/07Press Release
Phase 2 clinical trial initiated for the treatment of cutaneous warts, a human papillomavirus infection.
- Development of a novel antiviral drug against human papillomavirus -
2022/08/26Announcement
An interview with our President Kuroishi was published in the LINK-J (Life Science Innovation Network Japan).
Aiming to "stop cancer" of virus-infected cervical tissue! KinoPharma, Inc. takes on the challenge of developing new antiviral drugs.2023/04/07Press Release
Phase 2 clinical trial initiated for the treatment of cutaneous warts, a human papillomavirus infection.
- Development of a novel antiviral drug against human papillomavirus -
2020/07/06Press Release
Kinopharma is delighted to announce the registration of the first subject in phase 1/2 clinical studies in Korea evaluating the safety and efficacy of the anti-HPV agent, Kinopharma’s flagship program, in patients with cervical intraepithelial neoplasia (CIN).
Cervical intraepithelial neoplasia (CIN) is human papillomavirus (HPV) infection of the cervix that could potentially lead to cervical cancer. Currently, there are no approved antiviral drugs for the treatment of CIN. Our clinical candidate anti-HPV agent is intended to treat CIN by removing any types of HPV from the cervix. We aim for the fastest approval of the anti-HPV agent.
2020/01/14Press Release
ASKA Pharmaceutical and KinoPharma Entered into Option Agreement for Treatment of Cervical Dysplasia.
View the press release (PDF)2023/06/12Announcement
Patient enrollment has begun for a Phase II clinical trial for common warts.
For details, please refer to the following website.
2022/08/26Announcement
An interview with our President Kuroishi was published in the LINK-J (Life Science Innovation Network Japan).
Aiming to "stop cancer" of virus-infected cervical tissue! KinoPharma, Inc. takes on the challenge of developing new antiviral drugs.2022/08/18Announcement
KinoPharma is pleased to announce that it has entered into a co-development and commercialization agreement with IWAKI SEIYAKU Co., Ltd. for the treatment of warts caused by human papillomavirus (HPV).
View the announcement (PDF)About KinoPharma
KinoPharma is a clinical stage biopharma to research and develop small-molecule drugs based on new concept in areas of high medical need, such as antiviral drugs, and provide them to patients around the world who are waiting for them as quickly as possible.
Business
Cervical cancer is caused by human papillomavirus (HPV) infection, which not only kills many women, but also causes the loss of the uterus through surgery. We are committed to developing drugs that can treat this disease before it develops.
Research and Development
We take a different approach to discovering and developing next generation antiviral drugs from previous antiviral strategies.
